Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Sui TVL reaches $500m, more than doubles in January

Sui TVL reaches $500m, more than doubles in January

2024/02/04 19:55

The total locked-in value (TVL) of L1 blockchain Sui has now reached $500 million, achieving the milestone in less than nine months, according to data released by the official X account.Sui TVL grew 15x in the last five months of 2023 and more than doubled in January 2024.The total value of the blockchain is now at $1.5 billion, with the total value of the blockchain reaching $700 million in the last five months. Additionally, activity on the Sui chain is growing, with DeFi weekly transaction volume soaring over 70% to over $770 million last week, placing Sui in the top 5 most active blockchains.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56